Abstract
Until 4–5 years ago the hot topics in clinical colorectal cancer research were scheduling of 5-fluorouracil (5-FU) and its biochemical modulation. The long series of clinical failures on one side and the lack of strong evidence for something new coming up soon, generated the feeling that several years should pass before seeing appreciable progress in the clinical management of this disease. The situation has changed dramatically. Recently, in the last few years, a series of well-designed, well-conducted, randomized studies have demonstrated the value of CPT-11 as second line treatment of patients with advanced colorectal cancer (1,2) and subsequently the value of CPT-11 + 5-FU in the front line treatment of this disease (3–5). Oxaliplatin is somewhat behind CPT-11, but it elicits similar optimism among oncologists, particularly in Europe (6,7). although from a research perspective the small improvements afforded by the two new agents, particularly CPT-11, must be greeted as major breakthroughs, caution must be exercised from a broader perspective. The very small (< 3 mo) advantage in survival for CPT-11 + 5-FU combination vs 5-FU alone must be weighed against the increased toxicity and cost of the combinations. It is thus a pity that most of the research aimed at defining the best 5-FU schedule and modulation has been dropped: first, because the issue whether the new agents are most effective when given in combination or sequentially after 5-FU failure is still not solved; second, because it is likely that each of the new agents produces different effects depending on the schedule of 5-FU used when given in combination.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cunningham D, Pyrrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–1418.
Rougier P, Van Custem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407–1412.
Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal caner: a multicentre randomised trial. Lancet 2000; 355: 1041–1047.
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New Engl J Med 2000; 343: 905–914.
Saltz JB, Douillard J, Pirotta N, et al. Combined analysis of two phase III randomized trials comparing irinotecan, fluorouracil, leucovorin vs fluororuacil alone as first-line therapy of previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 938.
Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR Eur J Cancer 1999; 35: 1338–1342.
Giachetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of mletastatic colorectal cancer. J Clin Oncol 2000; 18: 136–147.
Rosen PJ, Amado R, Hecht JR, et al. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 5D.
Bergsland E, Hurwitz H, Fehrenbacher L. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000; 19: 936.
Reid T, Galanis E, Abbruzzese J, et al. Hepatic artery infusion of onyx-015, a selectively-replicanting adenovirus in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver Proc Am Soc Clin Oncol 2000; 19: 953.
Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer: a tale of two drugs. Implications for biochemical modulation. J Clin Oncol 1997; 15: 368–381.
Fraile RJ, Baker LH, Buroker TR, et al. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980; 40: 2223–2228.
Grem JL. Fluorinated pyrimidines, in Chabner BA, Collins JM (eds): Cancer Chemotherapy. Principles and practice. Philadelphia, PA, Lippincott, 1990,pp. 180–224.
Nord LD, Stolfi RL, Martin DS. Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue: correlation of antitumor activity with dosage and FUra incorporation into RNA. Biochem Pharmacol 1992; 43: 2543–2549.
Evans RM, Laskin JD, Hakala MT. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res 1980; 40: 4113–4122.
Wilkinson D, Crumly J. The mechanism of 5-fluorouridine toxicity in Novikoff hepatoma cells. Cancer Res 1976; 36: 4032–4038.
Maybaum J, Ullman B, Mandel HG, et al. Regulation of RNA- and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res 1980; 40: 4209–4215.
Radparvar S, Houghton PJ, Germain G, Pennington J, Rahman A, Houghton JA. Cellular pharmacology of 5fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency. Biochem Pharmacol 1990; 39: 1759–1765.
Piper AA, Fox RM Biochemical basis for the differential sensitivity of human T- and B-lymphocyte lines to 5-fluorouracil. Cancer Res 1982; 42: 3753–3760.
Washtien WL. Comparison of 5-fluorouracil metabolism in two human gastrointestinal tumor cell lines. Cancer Res 1984; 44: 909–914.
Pritchard DM, Watson AJM, Potten CS, Jackman AL, Hickman JA. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvment of RNA perturbation. Proc Natl Acad Sci USA 1997; 94: 1795–1799.
Jackman AL, Ford HE, Farrugia DC, et al. The effects of Raltitrexed (`Tomudex’), ZD9331 (`Vamidex’) and 5-FU on plasma dUrd, a surrogate marker of thymidylate synthase inhibition. Proc Am Soc Clin Oncol 2000; 19: 183a.
Santelli G, Valeriote F. Schedule-dependent cytotoxicity of 5-fluorouracil in mice. J Natl Cancer Inst 1986; 76: 159–164.
Calabro-Jones PM, Byfield JE, Ward JF, et al. Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res 1982; 42: 4413–4420.
Aschele C, Sobrero A, Faderan MA, et al. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52: 1855–1864.
Pizzorno G, Handschumacher RE. Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. Biochem Pharmacol 1995; 49: 559–565.
Wooley P, Ayoob M, Smith FR A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (Allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil. J Clin Oncol 1985; 3: 103–109.
Herrmann R, Knuth A, Kleeberg U, et al. Sequential methotrexate and 5-fluorouracil vs 5-fluorouracil alone in metastatic colorectal cancer. Ann Oncol 1992; 3: 539–543.
Seifert P, Baker LH, Reed ML, et al. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123–128.
Trump DL, Egorin MJ, Forrest A. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 1991; 11: 2027–2035.
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16: 301–308.
Mori A, Bertoglio S, Guglielmi A, et al. Activity of continuous infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 1993; 33: 179–180.
Izzo J, Zarba JJ, Rougier P, et al. Low dose 5-FU continuous infusion in advanced colorectal cancer: clinical evidence for reversal of acquired/intrinsic resistance to 5-FU or 5-FU folinic acid. Proc Am Ass Cancer Res 1992; 33: 217.
Hartmann H, Kennsinger A, Lemon H. Five days continuous infusion 5-fluorouracil for advanced colorectal gastric and pancreatic adenocarcinomas. J Surg Oncol 1979; 11: 227–238.
Zaniboni A, Labianca R, Martignoni G, et al. Sequential methotrexate and 5-fluorouracil as second line chemotherapy for advanced colorectal cancer pretreated with 5-fluorouracil and leucovorin: a GISCAD study. J Chemother 1996; 8: 82–84.
De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1998; 24: 1499–1503.
De Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997; 15: 808–815.
Jodrell DI, Murray LS, Reed NS, et al. Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK? Br J Cancer 1994; 70: 749–752.
Seymour MT, Slevin M, Cunningham D, et al. A randomized trial to assess the addition of interferon alpha 2a to 5-fluorouracil and leucovorin in advanced colorectal cancer. Br J Cancer 1994; 69: 24.
Hanna CL, Mc Kinna FE, Williams LB, et al. High dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Br J Cancer 1995; 72: 774–776.
De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–2947.
Leichman CG, Leichman L, Spears CP, et al. Prolonged infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst 1993; 85: 41–44.
Beck A, Etienne MC, Chéradame S, et al. Wide range for optimal concentration of folinic acid in fluorouracil modulation-Experimental data on human tumour cell lines. Eur J Cancer 1994; 30A: 1522–1526.
Jolivet J. Role of leucovorin dosing and administration schedule. Eur J Cancer 1995; 31A: 1311–1315.
Moran RG, Scanlon KL. Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 1991; 51: 4618–4623.
Waxman S, Bruckner H. The enhancement of 5-fluorouracil antimetabolic activity by leucovorin, menadione and a-tocopherol. Eur J Cancer Clin Oncol 1982; 18: 685–692.
Sobrero AF, Bertino JR. Sequence-dependent synergism between dichloromethotrexate and 5-fluorouracil in a human colon carcinoma cell line. Cancer Res 1983; 43: 4011–4013.
van der Wilt CL, Braakhuis BJM, Pinedo HM, et al. Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect? Int J Cancer 1995; 61: 672–678.
Sobrero AF, Romanini A, Russello et al. Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction. Eur J Cancer Clin Oncol 1989; 25: 977–982.
van der Wilt CL, Peters GJ. New targets for pyrimidine antimetabolites in the treatment of solid tumours. Pharm World Sci 1994; 16: 84–103.
Nadal JC, Van Groeningen CJ, Pinedo HM, et al. In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma. Biomed Pharmacother 1988; 42: 387–393.
Houghton JA, Williams LG, Loftin SK, et al. Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemother Pharmacol 1992; 30: 423–432.
Rustum YM. Selective modulation of 5-fluorouracil action in patients with colorectal carcinoma. Chemioterapia 1985; 4: 377–382.
Cao S, Duranni F, Rustum YM: Antitumor activity of fluorouracil/6-(RS)-leucovorin (FUra/LV) in rats bearing colon carcinoma: role of dose and schedule. Proc Am Assoc Cancer Res 1992; 33: 422.
Petrelli N, Douglass OH Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419–1426.
Lokich JJ, Phillips D, Green R, et al. 5-fluorouracil and methotrexate administered simultaneously as a continuous infusion, a phase I study. Cancer 1985; 56: 2395–2398.
Loeffler TM, Weber FW, Hausamen TU. Protracted continuous infusion 5-fluorouracil with intermittent high dose leucovorin in advanced and metastatic colorectal cancer: a pilot study. in Pinedo HM, Rustum YM (eds): Leucovorin modulation of fluoropyrimidines: a new frontier in cancer chemotherapy. London, Royal Society of Medicine Services Limited, 1989, pp 65–69.
Ardalan B, Chua L, Tian E, et al. A phase II study of weekly 24 hour infusion with high dose 5-fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991; 9: 625–630.
Tempero M, Berg A, Block M, et al. A phase II trial of protracted therapy with 5-fluorouracil and leucovorin in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1992; 11: 189.
Schmoll HI, Kohne CH, Lorenz M, et al. Weekly 24 hour infusion of high dose fluorouracil with or without folinic acid vs. bolus Fu/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): a randomized phase III study of the EORTC GITCCG and the AIO. Proc Am Soc Clin Oncol 2000; 19: 241a.
Sobrero AF, Aschele C, Guglielmi A, et al. Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer. Clin Cancer Res 1995; 1: 955–960.
Guglielmi A, Aschele C, Mori A, et al. In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells. Clin Cancer Res 1995; 1: 334–341.
Aschele C, Guglielmi A, Frassineti GL, et al. Schedule selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study. British J Cancer 1998; 77: 341–346.
Sobrero A, Zaniboni A, Frassineti GL, et al. Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study Ann Oncol 2000; 11: 1413–1428.
Lévi F, Zidani R, Misset JL, et al. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681–686.
Lévi FA, Zidani R, Vannetzel J-M, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608–1617.
Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 2950–2958.
Ross P, Norman A, Cunningham D, et al. A prospective randomized trial of protracted venous infusion fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997; 8: 995–1001.
Sobrero A, Guglielmi A, Cirillo M, et al. Highly effective, low cost chemotherapy for advanced colorectal cancer: a multicentric phase II study. Brit J Cancer 2001; in press.
Janinis J, Papakostas P, Samelis G, Skarlos D, Papagianopoulos P, Fountzilas G. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann Oncol 2000; 11: 163–167.
Souglakos J, Kouroussis C, Ziras N, et al. First line treatment with 5-fluorouracil (5-FU), leucovorin (LV), and oxaloplatin (1-OHP) in advanced colorectal cancer (ACC): a multicenter phase II study. Proc Am Soc Clin Oncol 2000, 302a.
Cheeseman SL, Crosse B, Chester JD, Richards FJ, Seymour MT. Second-line combination Oxaliplatin, Leucovorin, and 5FU (“OxMdG) in patients with 5FU-resistant colorectal cancer (CRC). Proc Am Soc Clin Oncol 2000; 19: 282.
Kouroussis C, Souglakos J, Giannakanis T, et al. Biweekly oxaliplatin (1-OHP) with high-dose leucovorin (LV) and 5-fluorouracil (5-FU) in irinotecan pretreated patients with advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2000; 19: 282.
Abad A, Navarro M, Sastre J, et al. Biweekly oxaliplatin (OXA) plus weekly 48hr continuous infusion (ci)5FU (TTD regimen) in first line treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2000; 19: 300a.
Giornelli G, Roca E, Chacon M, Martin C, Wasserman E. Bimonthly oxaliplatin (1-OHP) and weekly bolus 5-fluorouracil (5-FU) and folinic acid (FA) in patients (Pts) with metastatic colorectal cancer (CRC): a feasible and active regimen. Proc Am Soc Clin Oncol 2000; 19: 295a.
Hochster HS, Chachoua A, Wernz J, Escalon J, Martinez S, Muggia F. Oxaliplatin with weekly bolus 5FU and low-dose leucovorin (LV): early report of high activity in first line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2000; 19: 289a. 2000.
Vazquez S, Mel J, Sabin P, Alvarez E, Quintero G. Irinotecan (CPT-11) in combination with 5fluorouracil/folinic acid (5-FU/FA) as a weekly schedale in previously untreated patients with metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2000; 19: 316a.
Salgado M, Firida J, Mata J, et al. A phase II study of weekly irinotecan (CPT-11) combinated with folinic acid and 5-FU in pretreated advanced colorectal cancer (CRC) patients. Proc Am Soc Clin Oncol 2000; 19: 296a.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sobrero, A.F., Belvedere, O. (2003). Relevance of Scheduling to the Efficacy of 5-Fluorouracil Alone and in Combination with Other Agents. In: Rustum, Y.M. (eds) Fluoropyrimidines in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-337-8_8
Download citation
DOI: https://doi.org/10.1007/978-1-59259-337-8_8
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-274-2
Online ISBN: 978-1-59259-337-8
eBook Packages: Springer Book Archive